LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) (LUNAR-4)
LUNAR-4: Pilot, Single Arm, Open-Label, Multinational Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) Previously Treated With a PD-1/PD-L1 Inhibitor and Platinum-Based Chemotherapy
Sponsor: NovoCure GmbH
A PHASE2 clinical study on Non-Small Cell Lung Cancer (NSCLC), this trial is ongoing. The trial is conducted by NovoCure GmbH and has accumulated 9 data snapshots since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
9 versions recorded-
Nov 2025 — Present [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2025 — Nov 2025 [monthly]
Recruiting PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Recruiting PHASE2
-
Jun 2025 — Aug 2025 [monthly]
Recruiting PHASE2
-
May 2025 — Jun 2025 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Mar 2025 — May 2025 [monthly]
Recruiting PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Feb 2025 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2024 — Nov 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- NovoCure GmbH
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Arnhem, Netherlands , Bergamo, Italy , Boulogne-Billancourt, France , Créteil, France , Elche, Spain , Krakow, Poland , Lleida, Spain , Lublin, Poland , Lyon, France , Madrid, Spain and 13 more locations